SLRX:NSD- (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.8

Change

-0.03 (-4.17)%

Market Cap

N/A

Volume

0.02M
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.99 (+0.45%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

+13.54 (+2.29%)

USD 65.38B
ARGX argenx NV ADR

+4.71 (+0.82%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

+7.34 (+2.57%)

USD 32.75B
ONC BeiGene, Ltd.

+6.27 (+2.61%)

USD 27.70B
SMMT Summit Therapeutics PLC

+0.17 (+0.65%)

USD 27.07B
RPRX Royalty Pharma Plc

+0.01 (+0.03%)

USD 18.40B
INSM Insmed Inc

+2.85 (+4.29%)

USD 11.84B
INCY Incyte Corporation

+1.11 (+1.71%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

+0.46 (+0.79%)

USD 11.29B

ETFs Containing SLRX

SRET Global X SuperDividend® .. 3.56 % 0.59 %

+0.11 (+0.53%)

USD 0.18B
REM iShares Mortgage Real Est.. 3.19 % 0.48 %

+0.17 (+0.53%)

USD 0.55B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -56.52% 17% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.52% 17% F 9% A-
Trailing 12 Months  
Capital Gain -78.49% 18% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -78.49% 18% F 8% B-
Trailing 5 Years  
Capital Gain -99.60% 6% D- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.60% 6% D- 2% F
Average Annual (5 Year Horizon)  
Capital Gain 92.12% 84% B 93% A
Dividend Return 92.12% 84% B 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 893.66% 12% F 4% F
Risk Adjusted Return 10.31% 63% D 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.